GlassScriptPhysician profile
Anne Adkins
NPI 1730420944
$2,571.87
in general payments reported to CMS, 2019-2025
23 companies · $248 in 2025
The $248 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,001 · 2022: $778 · 2023: $430 · 2024: $114 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $792.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $426.15 | 2021-2025 | Belbuca, Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $299.80 | 2021-2025 | Relistor |
| Ibsa Pharma INC. | $254.32 | 2021-2024 | Tirosint, Licart, Tirosint |
| Scilex Pharmaceuticals INC. | $227.98 | 2021-2023 | Ztlido |
| Lilly USA, LLC | $173.31 | 2021-2023 | Reyvow, Emgality |
| Abbvie INC. | $150.55 | 2021 | |
| Forte Bio-Pharma LLC | $149.61 | 2025 | Prolate, Nalocet, Tanlor |
| Biohaven Pharmaceutical Holding Company LTD. | $142.49 | 2022 | |
| Eisai INC. | $134.25 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $97.53 | 2021 | |
| Redhill Biopharma INC. | $85.51 | 2021-2022 | |
| Grt US Holding, INC. | $73.48 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $68.77 | 2021-2023 | Belsomra |
| Avanir Pharmaceuticals, INC. | $56.74 | 2022 | |
| Amgen INC. | $52.21 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $43.42 | 2021 | |
| Almatica Pharma LLC | $24.95 | 2024 | Teriparatide |
| Upsher-Smith Laboratories LLC | $21.79 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.34 | 2021 | |
| Lundbeck LLC | $19.43 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.89 | 2023 | Quviviq |
| Hikma Pharmaceuticals USA | $16.60 | 2022 | |
| Averitas Pharma INC. | $15.75 | 2023 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Adkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.